Burk K - Search Results

1

The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor.

Holen K, Saltz LB, Hollywood E, Burk K, Hanauske AR. Holen K, et al. Among authors: burk k. Invest New Drugs. 2008 Feb;26(1):45-51. doi: 10.1007/s10637-007-9083-2. Epub 2007 Oct 9. Invest New Drugs. 2008. PMID: 17924057 Clinical Trial.

2

Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion.

Rassmann I, Thödtmann R, Mross M, Hüttmann A, Berdel WE, Manegold C, Fiebig HH, Kaeser-Fröhlich A, Burk K, Hanauske AR. Rassmann I, et al. Among authors: burk k. Invest New Drugs. 1998-1999;16(4):319-24. doi: 10.1023/a:1006293830585. Invest New Drugs. 1998. PMID: 10426664 Clinical Trial.

3

Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611. A study by the AIO groups PHASE-I and APOH.

Mross K, Hüttmann A, Herbst K, Hanauske AR, Schilling T, Manegold C, Burk K, Hossfeld DK. Mross K, et al. Among authors: burk k. Cancer Chemother Pharmacol. 1996;38(3):217-24. doi: 10.1007/s002800050474. Cancer Chemother Pharmacol. 1996. PMID: 8646795 Clinical Trial.

4

Phase II study of MTX-HSA in combination with cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma.

Bolling C, Graefe T, Lübbing C, Jankevicius F, Uktveris S, Cesas A, Meyer-Moldenhauer WH, Starkmann H, Weigel M, Burk K, Hanauske AR. Bolling C, et al. Among authors: burk k. Invest New Drugs. 2006 Nov;24(6):521-7. doi: 10.1007/s10637-006-8221-6. Invest New Drugs. 2006. PMID: 16699974 Clinical Trial.

5

Tissue disposition and plasma concentrations of idarubicin after intravesical therapy in patients with bladder tumors.

Mross K, Hamm K, Schultze-Seemann W, Burk K, Hossfeld DK. Mross K, et al. Among authors: burk k. Cancer Chemother Pharmacol. 1992;29(6):490-4. doi: 10.1007/BF00684854. Cancer Chemother Pharmacol. 1992. PMID: 1568293

6

Pharmacokinetics and metabolism of iodo-doxorubicin and doxorubicin in humans.

Mross K, Mayer U, Hamm K, Burk K, Hossfeld DK. Mross K, et al. Among authors: burk k. Eur J Clin Pharmacol. 1990;39(5):507-13. doi: 10.1007/BF00280945. Eur J Clin Pharmacol. 1990. PMID: 2076745

7

Toxicity, pharmacokinetics and metabolism of iododoxorubicin in cancer patients.

Mross K, Mayer U, Langenbuch T, Hamm K, Burk K, Hossfeld D. Mross K, et al. Among authors: burk k. Eur J Cancer. 1990;26(11-12):1156-62. doi: 10.1016/0277-5379(90)90276-y. Eur J Cancer. 1990. PMID: 2149998

8

[Iodo-doxorubicin, a new anthracycline derivative. Current state of progress].

Mross KB, Langenbuch T, Burk K, Hossfeld DK. Mross KB, et al. Among authors: burk k. Onkologie. 1990 Oct;13(5):346-51. doi: 10.1159/000216794. Onkologie. 1990. PMID: 2082229 Review. German.

9

Intravesical idarubicin--a phase-I study.

Schultze-Seemann W, Mross K, Burk K, Sommerkamp H. Schultze-Seemann W, et al. Among authors: burk k. Urol Res. 1994;22(2):99-104. doi: 10.1007/BF00310999. Urol Res. 1994. PMID: 7974920 Clinical Trial.

10

Weekly chemotherapeutic regimen in metastatic prostate cancer.

Burk K. Burk K. Prog Clin Biol Res. 1989;303:261-75. Prog Clin Biol Res. 1989. PMID: 2674989 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

240 results

Search Page

Filters